
## Nipun B Merchant

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4023653/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	ASO Author Reflections: Pancreatic Resection Margins—Chasing Moons. Annals of Surgical Oncology, 2022, 29, 1551-1552.	1.5	1
2	Landmark Series: Importance of Pancreatic Resection Margins. Annals of Surgical Oncology, 2022, 29, 1542-1550.	1.5	5
3	Interleukin-1 signaling in solid organ malignancies. Biochimica Et Biophysica Acta: Reviews on Cancer, 2022, 1877, 188670.	7.4	2
4	lpilimumab/Nivolumab Therapy in Patients With Metastatic Pancreatic or Biliary Cancer With Homologous Recombination Deficiency Pathogenic Germline Variants. JAMA Oncology, 2022, 8, 938.	7.1	28
5	ASO Author Reflections: Should we Stick our Neck Out for Pancreatic Neck Margins During Pancreaticoduodenectomy After Neoadjuvant Therapy?. Annals of Surgical Oncology, 2022, , 1.	1.5	0
6	Intraoperative Pancreatic Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Adenocarcinoma in the Era of Neoadjuvant Therapy: A Multi-institutional Analysis from the Central Pancreatic Consortium. Annals of Surgical Oncology, 2022, 29, 6004-6012.	1.5	4
7	Abstract 1565: Targeting stromal-specific p38 MAPK signaling to stifle inflammatory reprogramming of cancer-associated fibroblasts in pancreatic cancer. Cancer Research, 2022, 82, 1565-1565.	0.9	0
8	Obesity enriches for tumor protective microbial metabolites and treatment refractory cells to confer therapy resistance in PDAC. Gut Microbes, 2022, 14, .	9.8	10
9	Surgical management of hepatocellular carcinoma patients with portal vein thrombosis: The United States Safety Net and Academic Center Collaborative Analysis. Journal of Surgical Oncology, 2021, 123, 407-415.	1.7	8
10	Disparities in Presentation at Time of Hepatocellular Carcinoma Diagnosis: A United States Safety-Net Collaborative Study. Annals of Surgical Oncology, 2021, 28, 1929-1936.	1.5	7
11	ASO Author Reflections: National Institutes of Health Funding to Surgical Oncology Research. Annals of Surgical Oncology, 2021, 28, 4203-4204.	1.5	0
12	National Institutes of Health Research Funding to Academic Surgical Oncologists: Who Are We and Where Do We Stand?. Annals of Surgical Oncology, 2021, 28, 4195-4202.	1.5	5
13	Contemporary Reappraisal of Intraoperative Neck Margin Assessment During Pancreaticoduodenectomy for Pancreatic Ductal Adenocarcinoma. JAMA Surgery, 2021, 156, 489.	4.3	8
14	Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2021, 20, 1246-1256.	4.1	18
15	Survival inequity in vulnerable populations with early-stage hepatocellular carcinoma: a United States safety-net collaborative analysis. Hpb, 2021, 23, 868-876.	0.3	7
16	National Institutes of Health Career Development (K) Awards to Young Surgeons. Annals of Surgery, 2021, 274, 549-555.	4.2	5
17	Attrition during neoadjuvant chemotherapy for gastric adenocarcinoma is associated with decreased survival: A United States Safetyâ€Net Collaborative analysis. Journal of Surgical Oncology, 2021, 124, 1317-1328.	1.7	2
18	Targeting Tumor–Stromal IL6/STAT3 Signaling through IL1 Receptor Inhibition in Pancreatic Cancer. Molecular Cancer Therapeutics, 2021, 20, 2280-2290.	4.1	23

NIPUN B MERCHANT

#	Article	IF	CITATIONS
19	Ras-p53 genomic cooperativity as a model to investigate mechanisms of innate immune regulation in gastrointestinal cancers. Oncotarget, 2021, 12, 2104-2110.	1.8	5
20	Multimodality Therapy in Operable Pancreatic Cancer: Should We Sequence Surgery Last?. Annals of Surgical Oncology, 2021, 28, 1884-1886.	1.5	4
21	A Call for Caution in Overinterpreting Exceptional Outcomes After Radical Surgery for Pancreatic Cancer. Annals of Surgery, 2021, 274, e82-e84.	4.2	14
22	Utility of Radiation After Neoadjuvant Chemotherapy for Surgically Resectable Esophageal Cancer. Annals of Surgical Oncology, 2020, 27, 662-670.	1.5	2
23	Stroma secreted IL6 selects for "stem-like―population and alters pancreatic tumor microenvironment by reprogramming metabolic pathways. Cell Death and Disease, 2020, 11, 967.	6.3	27
24	Neoadjuvant Therapy. Advances in Surgery, 2020, 54, 49-68.	1.3	5
25	A Novel Interdisciplinary Iterative Approach for Optimizing the Electronic Health Record to Improve Perioperative Efficiency. Annals of Surgery, 2020, Publish Ahead of Print, 669-675.	4.2	2
26	Patterns of National Institutes of Health Grant Funding to Surgical Research and Scholarly Productivity in the United States. Annals of Surgery, 2020, 272, 539-546.	4.2	19
27	Pre-procedural screening for COVID-19 with nasopharyngeal polymerase chain reaction testing. British Journal of Anaesthesia, 2020, 125, e422-e424.	3.4	4
28	Minimally Invasive Surgery is Associated with an Increased Risk of Postoperative Venous Thromboembolism After Distal Pancreatectomy. Annals of Surgical Oncology, 2020, 27, 2498-2505.	1.5	9
29	Combined Src/EGFR Inhibition Targets STAT3 Signaling and Induces Stromal Remodeling to Improve Survival in Pancreatic Cancer. Molecular Cancer Research, 2020, 18, 623-631.	3.4	32
30	The Miami International Evidence-based Guidelines on Minimally Invasive Pancreas Resection. Annals of Surgery, 2020, 271, 1-14.	4.2	294
31	Deciphering high risk molecular alterations in gastrointestinal malignancy utilizing an extreme outlier strategy. Oncoscience, 2020, 7, 26-29.	2.2	4
32	Increased MTH1-specific 8-oxodGTPase activity is a hallmark of cancer in colon, lung and pancreatic tissue. DNA Repair, 2019, 83, 102644.	2.8	18
33	Radiation Therapy for Pancreatic Cancer: Executive Summary of an ASTRO Clinical Practice Guideline. Practical Radiation Oncology, 2019, 9, 322-332.	2.1	121
34	Racial and ethnic disparities in a stateâ€wide registry of patients with pancreatic cancer and an exploratory investigation of cancer cachexia as a contributor to observed inequities. Cancer Medicine, 2019, 8, 3314-3324.	2.8	21
35	Survival Outcomes Associated With Clinical and Pathological Response Following Neoadjuvant FOLFIRINOX or Gemcitabine/Nab-Paclitaxel Chemotherapy in Resected Pancreatic Cancer. Annals of Surgery, 2019, 270, 400-413.	4.2	113
36	Urolithin A, a Novel Natural Compound to Target PI3K/AKT/mTOR Pathway in Pancreatic Cancer. Molecular Cancer Therapeutics, 2019, 18, 301-311.	4.1	64

NIPUN B MERCHANT

#	Article	IF	CITATIONS
37	Cyst location and presence of high grade dysplasia or invasive cancer in intraductal papillary mucinous neoplasms of the pancreas: a seven institution study from the central pancreas consortium. Hpb, 2019, 21, 482-488.	0.3	9
38	Src kinase inhibition restores E-cadherin expression in dasatinib-sensitive pancreatic cancer cells. Oncotarget, 2019, 10, 1056-1069.	1.8	10
39	Tobacco Carcinogen–Induced Production of GM-CSF Activates CREB to Promote Pancreatic Cancer. Cancer Research, 2018, 78, 6146-6158.	0.9	30
40	Inverse Correlation of STAT3 and MEK Signaling Mediates Resistance to RAS Pathway Inhibition in Pancreatic Cancer. Cancer Research, 2018, 78, 6235-6246.	0.9	61
41	Pancreatic Neuroendocrine Tumors (panNETs): Analysis of Overall Survival of Nonsurgical Management Versus Surgical Resection. Journal of Gastrointestinal Surgery, 2017, 21, 855-866.	1.7	63
42	The Impact of Surgeon Volume on Outcomes After Pancreaticoduodenectomy: a Meta-analysis. Journal of Gastrointestinal Surgery, 2017, 21, 1723-1731.	1.7	49
43	Adiponectin receptor agonists inhibit leptin induced pSTAT3 and <i>in vivo</i> pancreatic tumor growth. Oncotarget, 2017, 8, 85378-85391.	1.8	45
44	Pancreatic stellate cell secreted IL-6 stimulates STAT3 dependent invasiveness of pancreatic intraepithelial neoplasia and cancer cells. Oncotarget, 2016, 7, 65982-65992.	1.8	84
45	Delayed gastric emptying after pancreaticoduodenectomy. Journal of Surgical Research, 2016, 202, 380-388.	1.6	43
46	Phase I trial of vorinostat added to chemoradiation with capecitabine in pancreatic cancer. Radiotherapy and Oncology, 2016, 119, 312-318.	0.6	51
47	Neoadjuvant and adjuvant, floxuridine, leucovorin, oxaliplatin, and docetaxel (FLOD) in patients with locally advanced operable gastroesophageal adenocarcinoma: A phase II study with pathologic responses and long term follow-up Journal of Clinical Oncology, 2016, 34, 124-124.	1.6	0
48	Signal Transducer and Activator of Transcription 3, Mediated Remodeling of the Tumor Microenvironment Results in Enhanced Tumor Drug Delivery in a Mouse Model of Pancreatic Cancer. Gastroenterology, 2015, 149, 1932-1943.e9.	1.3	151